Invivyd

Invivyd has established the SPEAR Study Group with leading researchers to investigate monoclonal antibody therapy for Long COVID and Post-Vaccination Syndrome, following anecdotal reports of symptom relief with PEMGARDA.

Invivyd's CANOPY Phase 3 trial demonstrated that PEMGARDA (pemivibart) achieved an 84% relative risk reduction in symptomatic COVID-19 compared to placebo over six months (nominal p <0.0001).

Upstream Bio has appointed Stacy Price as Chief Technology Officer, bringing over 25 years of biotechnology experience to oversee technical operations and product development for verekitug.

Invivyd has submitted a Citizen Petition urging the FDA to reevaluate COVID-19 prevention strategies, emphasizing the need for monoclonal antibodies alongside vaccines in the endemic phase of the virus.

Invivyd has launched a discovery program for a measles monoclonal antibody (mAb) in response to direct requests from healthcare providers treating active measles cases and managing outbreaks.

Invivyd has signed a $30 million term loan facility with Silicon Valley Bank, providing non-dilutive capital access contingent on meeting specific milestones and conditions.

The FDA has rejected Invivyd's application to expand Pemgarda's emergency use authorization for treating mild to moderate COVID-19 in immunocompromised patients without alternative treatment options.

Invivyd's VYD2311 demonstrates positive safety and pharmacokinetic profiles in an ongoing Phase 1/2 clinical trial, with complete enrollment and dosing.

Invivyd's PEMGARDA (pemivibart) demonstrates consistent neutralizing activity against the dominant SARS-CoV-2 variant XEC in new in vitro data.

Invivyd's CANOPY phase 3 trial data demonstrates pemivibart's efficacy as pre-exposure prophylaxis (PrEP) for COVID-19, including protection against recent JN.1 sublineages.